Compounds > 1-(5-isoquinolinesulfonyl)-2-methylpiperazine
Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Akinetic-Rigid Variant of Huntington Disease

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, M1
Yasumura, D1
Ma, AA1
Matthes, MT1
Yang, H1
Nielson, G1
Huang, Y1
Szoka, FC1
Lavail, MM1
Diamond, MI1

Other Studies

1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Akinetic-Rigid Variant of Huntington Disease

ArticleYear
Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Electroretinography;

2013